Asset
Navepegritide
Ascendis Pharma A/S Ordinary Share
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06732895 | phase2 | recruiting | 2024-12-10 | 2027-08-01 | Ascendis Pharma A/S | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. |
| NCT05598320 | phase2_3 | completed | 2023-03-03 | 2024-08-09 | Ascendis Pharma Growth Disorders A/S | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia |
| NCT06079398 | phase2 | recruiting | 2024-01-23 | 2027-12-01 | Ascendis Pharma A/S | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 219164 | NDA | ASCENDIS PHARMA GROWTH DISORDERS AS |
Marketed products (3)
- YUVIWEL
- YUVIWEL
- YUVIWEL